New all‐oral HCV therapies for genotype 1: A final good‐bye to interferon

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107533/1/cld369.pd

Interview with american association for the study of liver diseases president Dr. Anna Lok

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136704/1/hep41038.pd

Reply:

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/86969/1/24520_ftp.pd

Progress in hepatitis B: A 30‐year journey through three continents

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107540/1/hep27120.pd

Hepatitis B Treatment: What We Know Now and What Remains to Be Researched

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/147072/1/hep41281.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/147072/2/hep41281_am.pd

Viral hepatitis and pregnancy

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/108668/1/cld367.pd

Reply

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149229/1/hep30564.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149229/2/hep30564_am.pd

Endpoints of hepatitis B treatment

The goal of hepatitis B treatment is to prevent the development of cirrhosis, liver failure, and hepatocellular carcinoma. Ideally, clinical studies should demonstrate that hepatitis B therapies can prevent liver-related complications; however, these clinical endpoints evolve over years or decades. Therefore, clinical trials have relied on intermediate endpoints to evaluate the efficacy of treatment and to determine when treatment can be stopped. Intermediate endpoints that have been used include biochemical, histological, virological, and serological endpoints. This review will discuss the validity of these intermediate endpoints as surrogates of clinical endpoints, and the rates at which these intermediate endpoints can be achieved with currently available therapies.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/79271/1/j.1365-2893.2010.01369.x.pd

Reply:

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/87032/1/24410_ftp.pd

Personalized treatment of hepatitis B

There are seven approved drugs for treatment of hepatitis B. Professional guidelines provide a framework for managing patients but these guidelines should be interpreted in the context of the individual patient's clinical and social circumstances. Personalized management of hepatitis B can be applied based on prediction of the individual patient's risk of cirrhosis and hepatocellular carcinoma to guide the frequency and intensity of monitoring and urgency of treatment. It can also be applied to decisions regarding when to start treatment, which drug to use, and when to stop based on the individual patient's disease characteristics, preference, comorbidities and other mitigating circumstances